Axantia is a holding company based in Dubai, United Arab Emirates, operating under the laws of the Dubai International Financial Centre (DIFC), United Arab Emirates.
The strategic vision of Axantia is to expand its presence in the health and pharmaceutical sector, focusing on enhancing capabilities, diversifying its product portfolio, and expanding its geographical reach.
Axantia owns the entire share capital of Pharma International Company (PIC) and Med City Pharma (MCP). Through its subsidiaries, Axantia develops, manufactures, markets and distributes generic medicines in over 19 countries in the Middle East and Africa.
The manufacturing capabilities of Axantia extends to General Formulations products and Cephalosporins (oral & injectable).
Axantia is owned joint by Al-Faisaliah Group and Sana Investments.
At Axantia we aim to be a leading pharmaceutical partner for key stakeholders, committed to improving patient health outcomes, reducing healthcare costs, through bringing best-in-class and high quality products.
Axantia has been a leading manufacturer of general formulations and Cephalosporins for over 20 years. It maintains a leading position in the cephalosporin market with products that are well suited for specific applications.
In order to maintain a competitive edge and stay on top of the latest industry trends, it is my responsibility as the CEO of Axantia to constantly build and shape our company into one that is resilient and innovative. By doing so, we can successfully compete in today's complex market environment. We are able to achieve this by attracting, developing and retaining dedicated and skilled talents who work together passionately. We do this by offering our employees a climate of responsibility, accountability and respect where every employee has the opportunity to excel and develop their full potential.
I hope that this website will help our stakeholders understand how we are addressing patients’ needs and what value we aim to deliver to society.